Luca Vangelista

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7546689/publications.pdf

Version: 2024-02-01

279798 233421 2,113 56 23 45 citations h-index g-index papers 56 56 56 2196 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis. Frontiers in Immunology, 2022, 13, 826418.	4.8	3
2	Picomolar detection of thrombin with fiber-optic ball resonator sensor using optical backscatter reflectometry. Optik, 2021, 241, 166969.	2.9	15
3	Perspectives on Assembling Coronavirus Spikes on Fiber Optics to Reveal Broadly Recognizing Antibodies and Generate a Universal Coronavirus Detector. Frontiers in Bioengineering and Biotechnology, 2021, 9, 637715.	4.1	O
4	Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses. Frontiers in Molecular Biosciences, 2020, 7, 226.	3.5	12
5	Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria. Cellular Immunology, 2020, 358, 104215.	3.0	11
6	Staphylococcus aureus Infection and Persistence in Chronic Rhinosinusitis: Focus on Leukocidin ED. Toxins, 2020, 12, 678.	3.4	25
7	Functionalized etched tilted fiber Bragg grating aptasensor for label-free protein detection. Biosensors and Bioelectronics, 2019, 146, 111765.	10.1	85
8	AllergoOncology: Microbiota in allergy and cancerâ€"A European Academy for Allergy and Clinical Immunology position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1037-1051.	5.7	17
9	Rational CCL5 mutagenesis integration in a lactobacilli platform generates extremely potent HIV-1 blockers. Scientific Reports, 2018, 8, 1890.	3.3	12
10	AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 328-340.	5.7	54
11	AllergoOncology – the impact of allergy in oncology: <scp>EAACI</scp> position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 866-887.	5.7	68
12	The Expanding Therapeutic Perspective of CCR5 Blockade. Frontiers in Immunology, 2017, 8, 1981.	4.8	83
13	Cutting Edge: IgE Plays an Active Role in Tumor Immunosurveillance in Mice. Journal of Immunology, 2016, 197, 2583-2588.	0.8	31
14	Combination of the CCL5-Derived Peptide R4.0 with Different HIV-1 Blockers Reveals Wide Target Compatibility and Synergic Cobinding to CCR5. Antimicrobial Agents and Chemotherapy, 2014, 58, 6215-6223.	3.2	6
15	Role and Redirection of IgE against Cancer. Antibodies, 2013, 2, 371-391.	2.5	1
16	An Antitumor Cellular Vaccine Based on a Mini-Membrane IgE. Journal of Immunology, 2012, 188, 103-110.	0.8	15
17	In Search of a Vaccine for Mouse Allergy: Significant Reduction of Mus m 1 Allergenicity by Structure-Guided Single-Point Mutations. International Archives of Allergy and Immunology, 2012, 157, 226-237.	2.1	22
18	Enhancement of Anti-HIV-1 Activity by Hot Spot Evolution of RANTES-Derived Peptides. Chemistry and Biology, 2012, 19, 1579-1588.	6.0	12

#	Article	IF	CITATIONS
19	154 Anti-HIV-1 RANTES Derivatives Acting as CCR5 Antagonists Present Full Additivity or Synergy in Combination With Different Entry/Fusion Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 63.	2.1	1
20	Molecular engineering of RANTES peptide mimetics with potent antiâ€HIVâ€1 activity. FASEB Journal, 2011, 25, 1230-1243.	0.5	21
21	226 Engineered Lactobacilli as a System to Screen Potent RANTES Mutants Acting as Live CCR5 Antagonist HIV-1 Blockers. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 98.	2.1	3
22	Engineering of $\langle i \rangle$ Lactobacillus jensenii $\langle i \rangle$ To Secrete RANTES and a CCR5 Antagonist Analogue as Live HIV-1 Blockers. Antimicrobial Agents and Chemotherapy, 2010, 54, 2994-3001.	3.2	56
23	IgE as Adjuvant in Tumor Vaccination. , 2010, , 215-229.		1
24	Antitumor IgE Adjuvanticity: Key Role of FcεRI. Journal of Immunology, 2009, 183, 4530-4536.	0.8	36
25	The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants. Protein Expression and Purification, 2009, 68, 34-41.	1.3	15
26	AllergoOncology: the role of IgEâ€mediated allergy in cancer. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1255-1266.	5.7	192
27	Large-scale expression and purification of the major HIV-1 coreceptor CCR5 and characterization of its interaction with RANTES. Protein Expression and Purification, 2008, 61, 155-162.	1.3	28
28	Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine, 2008, 26, 3008-3015.	3.8	39
29	Critical role of the N-loop and \hat{l}^21 -strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity. Biochemical and Biophysical Research Communications, 2006, 351, 664-668.	2.1	15
30	Unreliable Measurement of Basophil Maximum Leukotriene Release with the Bul`hlmann CAST 2000 Enzyme-Linked Immunosorbent Assay Kit. Vaccine Journal, 2006, 13, 420-422.	3.1	7
31	Membrane IgE Binds and Activates FclμRI in an Antigen-Independent Manner. Journal of Immunology, 2005, 174, 5602-5611.	0.8	23
32	Current Progress in the Understanding of IgE-Fcl $\hat{\mu}$ RI Interaction. International Archives of Allergy and Immunology, 2003, 131, 222-233.	2.1	9
33	A minimal receptor-Ig chimera of human FcεRI α-chain efficiently binds secretory and membrane IgE. Protein Engineering, Design and Selection, 2002, 15, 51-57.	2.1	9
34	Purification, Structural and Immunological Characterization of a Timothy Grass (Phleum pratense) Pollen Allergen, Phl p 4, with Cross-Reactive Potential. Biological Chemistry, 2002, 383, 1383-96.	2.5	21
35	Efficient Folding of the FclµRI l̂±-chain Membrane-proximal Domain D2 Depends on the Presence of the N-terminal Domain D1. Journal of Molecular Biology, 2002, 322, 815-825.	4.2	11
36	A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FclµRI interaction and reacts with receptor-bound IgE. Journal of Allergy and Clinical Immunology, 2001, 108, 409-416.	2.9	23

3

#	Article	IF	Citations
37	Membrane Immunoglobulins Are Stabilized by Interchain Disulfide Bonds Occurring within the Extracellular Membrane-Proximal Domain. Biochemistry, 2001, 40, 10686-10692.	2.5	17
38	A Highly Allergenic Fragment of the Major Timothy Grass Pollen Allergen, Phl p 5, Defined by a Human Monoclonal IgE Antibody. International Archives of Allergy and Immunology, 2001, 124, 80-84.	2.1	0
39	Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. FASEB Journal, 2001, 15, 2045-2047.	0.5	115
40	Ig modules as discrete structural units to exploit functional and structural aspects of Ig-like receptors., 2001,, 55-62.		1
41	A Human Monoclonal IgE Antibody Defines a Highly Allergenic Fragment of the Major Timothy Grass Pollen Allergen, Phl p 5: Molecular, Immunological, and Structural Characterization of the Epitope-Containing Domain. Journal of Immunology, 2000, 165, 3849-3859.	0.8	77
42	Purification, biochemical, and immunological characterisation of a major food allergen: different immunoglobulin E recognition of the apo- and calcium-bound forms of carp parvalbumin. Gut, 2000, 46, 661-669.	12.1	149
43	Calciumâ€dependent immunoglobulin E recognition of the apo†and calciumâ€bound form of a crossâ€reactive two EFâ€hand timothy grass pollen allergen, Phl p 7. FASEB Journal, 1999, 13, 843-856.	0.5	105
44	B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB Journal, 1999, 13, 1277-1290.	0.5	73
45	An in vitro Model for the Allergen–IgE–FcεRI Interaction. International Archives of Allergy and Immunology, 1999, 118, 116-118.	2.1	3
46	Molecular and Immunological Characterization of Carp Parvalbumin, a Major Fish Allergen. International Archives of Allergy and Immunology, 1999, 118, 306-308.	2.1	35
47	Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy. International Archives of Allergy and Immunology, 1999, 118, 218-219.	2.1	32
48	The immunoglobulin-like modules $\hat{Cl}\mu 3$ and $\hat{l}\pm 2$ are the minimal units necessary for human IgE-Fcl μRl interaction. Journal of Clinical Investigation, 1999, 103, 1571-1578.	8.2	29
49	Calcium–Binding Allergens: From Plants to Man. International Archives of Allergy and Immunology, 1998, 117, 160-166.	2.1	106
50	Division of the Major Birch Pollen Allergen, Bet ν 1, into Two Non-Anaphylactic Fragments. International Archives of Allergy and Immunology, 1997, 113, 246-248.	2.1	19
51	Bip 1, a Monoclonal Antibody with Specificity for the Major Birch Pollen Allergen Bet ν 1, Modulates IgE Binding to the Allergen. International Archives of Allergy and Immunology, 1997, 113, 260-261.	2.1	6
52	Molecular Characterization, Expression in Escherichia coli, and Epitope Analysis of a Two EF-Hand Calcium-Binding Birch Pollen Allergen, Bet ν 4. Biochemical and Biophysical Research Communications, 1997, 239, 197-204.	2.1	70
53	Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy Journal of Clinical Investigation, 1997, 99, 1673-1681.	8.2	186
54	The Elastic I-band Region of Titin is Assembled in a "Modular" Fashion by Weakly Interacting Ig-like Domains. Journal of Molecular Biology, 1996, 255, 604-616.	4.2	77

#	Article	IF	CITATION
55	Analysis of the localization of STE6/CFTR chimeras in a Saccharomyces cerevisiae model for the cystic fibrosis defect CFTRî"F508. Molecular Microbiology, 1996, 19, 1007-1017.	2.5	27
56	Structural Studies on the Zinc-endopeptidase Light Chain of Tetanus Neurotoxin. FEBS Journal, 1995, 229, 61-69.	0.2	4